To investigate whether the tumour perfusion change resulted in oxygenation changes, tumour hypoxia was assessed by immunohistochemical staining for the endogenous hypoxia marker CA9 [27], in Calu-3 and Calu-6 tumours harvested 2 h after the second dose of cediranib or vehicle treatment. Here, CA9 is linked to neoplasm.